Skip to Content

Even 1 Dose of Pfizer, AstraZeneca COVID Vaccines Offer Good Protection for People Over 80

MONDAY, March 8, 2021 -- Just one dose of the Pfizer or Oxford-AstraZeneca vaccines significantly reduces the risk of hospitalization for COVID patients in their 80s with preexisting health conditions, a preliminary study shows.

The findings are from AvonCAP, an ongoing surveillance project funded by Pfizer Inc. It gathers detailed information from two National Health Service (NHS) hospitals in Bristol, U.K., on every adult admitted with symptoms and/or X-ray evidence of acute respiratory disease.

Researchers identified 434 such patients between Dec. 18 (10 days after launch of the U.K.'s vaccine program) and Feb. 26. They were eligible for vaccination because they would be at least 80 years old by March 31.

To gauge the effectiveness of single doses of the vaccines, researchers compared immunization rates among adults with acute respiratory disease who tested either positive or negative for COVID when they were admitted to the hospital.

They also accounted for several factors that could affect a person's chances of getting COVID and of being vaccinated, including gender, economic status and living in a care home.

One dose of Pfizer vaccine was 71.4% effective after 14 days at preventing symptomatic illness severe enough to require hospitalization, the study found. Patients' median age was 87, meaning half were older, half younger.

One dose of the Oxford-AstraZeneca vaccine was 80.4% effective after 14 days. Patients' median age was 88, according to findings released March 3.

The Pfizer vaccine has been used in the U.K. since Dec. 8, and the Oxford-AstraZeneca vaccine has been in circulation since Jan. 4.

When researchers focused on data from early 2021, the effectiveness of a single dose of the two vaccines was nearly identical: Pfizer, 79.3%, and Oxford-AstraZeneca, 80.4%.

The findings are similar to those from other studies in Scotland and England, and have significant implications for countries developing COVID vaccination strategies for vulnerable elderly populations, according to the researchers.

"We are very pleased to share these early results that show the UK COVID-19 vaccine program is working better than we could have hoped," said chief study investigator Adam Finn, a professor of pediatrics at the University of Bristol.

"We are also delighted our findings could reduce the burden of serious illness in our elderly population and relieve the pressure on the NHS," he added in a university news release. "The AvonCAP study will continue to provide further and more detailed information as time goes on."

© 2021 HealthDay. All rights reserved.

Read this next

One Good Way to Help Beat COVID: Exercise

WEDNESDAY, April 14, 2021 -- Exercise guards against a host of chronic diseases that can plague people as they age, but can it also protect against severe cases of COVID-19? New...

Biden, Fauci Say Pause in J&J COVID Vaccine Is Sign That Safety Comes First

WEDNESDAY, April 14, 2021 -- The Biden Administration sought to reassure Americans on Tuesday that the pausing of Johnson & Johnson's coronavirus vaccine is science at work,...

Mom and Baby's Tale of Survival After Severe COVID Strikes in Pregnancy

WEDNESDAY, April 14, 2021 -- The emotional toll of having a baby can be huge under any circumstance, but what if you didn't know you gave birth until two weeks later, and you...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.